Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Stress Doppler echocardiography ‘reliable’ for early PAH detection in systemic sclerosis

Stress Doppler echocardiography ‘reliable’ for early PAH detection in systemic sclerosis

Oral PAH treatments stave off clinical decline

Oral PAH treatments stave off clinical decline

Prognosis still gloomy for idiopathic PAH

Prognosis still gloomy for idiopathic PAH

PAH diagnosis delayed for adult congenital heart disease patients

PAH diagnosis delayed for adult congenital heart disease patients

Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Noninvasive findings reduce catheterisation need in suspected PAH

Noninvasive findings reduce catheterisation need in suspected PAH

Early intensive epoprostenol yields best haemodynamic outcomes in PAH

Early intensive epoprostenol yields best haemodynamic outcomes in PAH

Meta-analysis supports ambrisentan efficacy

Meta-analysis supports ambrisentan efficacy

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Researchers call for earlier PAH diagnosis and treatment

Researchers call for earlier PAH diagnosis and treatment

Early decline in 6MWT distance predicts PAH worsening

Early decline in 6MWT distance predicts PAH worsening

Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 helps determine IPAH diagnosis

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Mechanistic subtypes of IPAH revealed

Mechanistic subtypes of IPAH revealed

Metabolic derangement may facilitate cell proliferation in PAH

Metabolic derangement may facilitate cell proliferation in PAH